Vaccine reduces cervical cancer rates by 87%

A group of researchers from the United Kingdom concluded that the Cervarix vaccine against human papillomavirus (HPV) introduced on September 1, 2008 in that European sector, reduced cervical cancer rates by up to 87% in women teenagers between 12 and 13 years old. The results were published in The Lancet.

It is estimated that in mid-2019 there were 450 fewer cases than cervical cancer and 17,200 fewer cases of pre-cancers than expected in the vaccinated population, according to the public health article.

Later in the manuscript it is noted that the estimated reduction in cervical cancer rates as a result of immunizations was reduced by 34% for women aged 16-18 years; and 62% for females between 14 and 16 years old.

The registries evaluated include information on diagnoses of this type of cancer from January 1, 2006 to June 30, 2019 in women aged 20 to 64 years residing in England, but focused on people in school years.

Often times, the human papillomavirus is transmitted sexually, according to a statement from the World Health Organization (WHO). “There are more than 100 types of HPV, each identified by a number. Some types of HPV can cause genital or anal warts, but they do not cause cancer. Genital warts are visible, soft, moist, skin-colored bumps ”, it is explained.

For its part, the Mayo Clinic emphasizes that when we are exposed to this virus, the immune system avoids it, but a small percentage of people do not get it. And because this agent survives for some time, it can trigger cancer cell outbreaks. Watery vaginal discharge, bleeding after intimate relationships, and pelvic pain are often warning features.

Dr Kate Soldan, from the UK Blood Safety, Hepatitis, Sexually Transmitted Infections and HIV Service, co-author of the Lancet article, agreed with the analysis and highlighted that this is the first direct evidence of a positive impact on a vaccination campaign to fight against HPV.

“We hope that these new results will foster acceptance, as the success of the vaccination program depends not only on the efficacy of the vaccine, but also on the proportion of the population vaccinated“Added Soldan.

The WHO, in 2020, highlighted the importance of 90% of 15-year-old adolescents being fully vaccinated, this time with the corresponding dose of Gardasil, approved by the FDA (US Food and Drug Administration). in 2006.

The Centers for Disease Control and Prevention (CDC) have confirmed the efficacy of the vaccine this year. In 2006, they had already recommended it for girls between 11 and 12 years old.